

Table S1. Clinical characteristics and genotype frequencies of TERT rs10069690 in the study population.

		Sum	CC	CT	TT
All subjects		649	326 (50.2%)	270 (41.6%)	53 (8.2%)
Patients		403	203 (50.4%)	168 (41.7%)	32 (7.9%)
Controls		246	123 (50.0%)	102 (41.5%)	21 (8.5%)
Patient subpopulations					
Age (years)	<55	171	88 (51.5%)	66 (38.6%)	17 (9.9%)
	≥55	232	115 (49.6%)	102 (44.0%)	15 (6.5%)
Menopausal status	pre	100	54 (54.0%)	36 (36.0%)	10 (10.0%)
	post	248	125 (50.4%)	105 (42.3%)	18 (7.3%)
	na	55	23 (41.8%)	27 (49.1%)	5 (9.1%)
Tumor size	pT1	174	84 (48.3%)	80 (46.0%)	10 (5.7%)
	pT2-4	157	86 (54.8%)	55 (35.0%)	16 (10.2%)
	other, na	73	34 (46.6%)	33 (45.2%)	6 (8.2%)
Tumor type	ductal	245	123 (50.2%)	101 (41.2%)	21 (8.6%)
	lobular	80	48 (60.0%)	27 (33.8%)	5 (6.3%)
	other, na	78	32 (41.0%)	40 (51.3%)	6 (7.7%)
Stage	0-1	141	65 (46.1%)	65 (46.1%)	11 (7.8%)
	2-4	186	103 (55.4%)	67 (36.0%)	16 (8.6%)
	other, na	76	35 (46.1%)	36 (47.4%)	5 (6.6%)
Grade	pG1-2	235	118 (50.2%)	99 (42.1%)	18 (7.7%)
	pG3	145	76 (52.4%)	57 (39.3%)	12 (8.3%)
	na	23	9 (39.1%)	12 (52.2%)	2 (8.7%)
Lymph node status	pN0	193	93 (48.2%)	81 (42.0%)	19 (9.8%)
	pN+	132	73 (55.3%)	53 (40.2%)	6 (4.5%)
	na	72	37 (51.4%)	34 (47.2%)	1 (1.4%)
ER status	pos	270	142 (52.6%)	112 (41.5%)	16 (5.9%)
	neg	117	54 (46.2%)	48 (41.0%)	15 (12.8%)
	na	16	7 (43.8%)	8 (50.0%)	1 (6.3%)
PR status	pos	186	101 (54.3%)	74 (39.8%)	11 (5.9%)
	neg	194	91 (46.9%)	84 (43.3%)	19 (9.8%)
	na	23	11 (47.8%)	10 (43.5%)	2 (8.7%)
HER2 status	pos	74	38 (51.4%)	29 (39.2%)	7 (9.5%)
	neg	293	144 (49.1%)	126 (43.0%)	23 (7.8%)
	na	36	21 (58.3%)	13 (36.1%)	2 (5.6%)
p53 status	pos	91	38 (41.8%)	47 (51.6%)	6 (6.6%)
	neg	257	134 (52.1%)	101 (39.3%)	22 (8.6%)
	na	55	31 (56.4%)	20 (36.4%)	4 (7.3%)
Ki67 pos cells	<50%	278	146 (52.5%)	113 (40.6%)	19 (6.8%)
	≥50%	28	11 (39.3%)	12 (42.9%)	5 (17.9%)
	na	97	46 (47.4%)	43 (44.3%)	8 (8.2%)
Tumor Subtype	Luminal A	233	119 (51.1%)	99 (42.5%)	15 (6.4%)
	Luminal B	41	22 (53.7%)	16 (39.0%)	3 (7.3%)
	HER2 type	33	16 (48.5%)	13 (39.4%)	4 (12.1%)
	Triple neg	60	25 (41.7%)	27 (45.0%)	8 (13.3%)
	na	36	21 (58.3%)	13 (36.1%)	2 (5.6%)

Numbers of all patients and controls, as well as number of patients in the indicated subpopulations are shown. Parenthesized numbers show the fraction of patients (%) with the indicated genotypes. ER, estrogen receptor; PR, progesterone receptor; na, status not available.